Review the sources used below for this article: This article references information from a study published in the BMJ: Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation
Most products sit on the surface of your scalp and never reach the target
[PubMed] [Google Scholar] 6
Following healthy human subjects infusion with native GLP-1, diastolic blood pressure (DBP) showed a slight increase, concomitant with a related increase in muscle sympathetic nerve activities (96)
Separate from diabetic retinopathy, recent research has examined whether semaglutide or tirzepatide may be associated with an increased risk of optic nerve disorders, including non-arteritic anterior ischemic optic neuropathy, or NAION
Abstract Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough therapies for type 2 diabetes mellitus (T2DM)
